Get to know our clinical trials

Clinical trial to evaluate the safety and efficacy of ARI0002h, a BCMA-targeted CAR-T cell therapy, for the initial treatment of patients with primary plasma cell leukemia

THE GEM-PLASMACAR STUDY IS A CLINICAL TRIAL FOR PEOPLE WITH A RECENT DIAGNOSIS OF PRIMARY PLASMA CELL LEUKEMIA (PPCL). IN THIS STUDY, WE AIM TO DETERMINE WHETHER ARI0002H CELLS ARE SAFE AND EFFECTIVE IN ELIMINATING THE DISEASE.

Navarre headquarters
Madrid headquarters
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase

Technical Summary

  • A PHASE II, MULTICENTER, OPEN-LABEL, PROSPECTIVE, NON-RANDOMIZED CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ARI0002H, A BCMA-TARGETED CAR-T CELL THERAPY, FOR THE INITIAL TREATMENT OF PATIENTS WITH PRIMARY PLASMA CELL LEUKEMIA
  • Code EudraCT: 2024-515053-21-00
  • Protocol number: GEM-PLASMACAR
  • Promoter: FUNDACIÓ DE RECERCA CLÍNIC BARCELONA-INSTITUT D¿INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER (IDIBA
  • Molecule/Drug: ARI0002h
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.